Difference between revisions of "Team:SDU-Denmark/Tour71"
| Line 2: | Line 2: | ||
<html> | <html> | ||
| − | < | + | <h2> Medical aspects </h2> |
<p class="intro"> Although there is no doubt that peptide aptamers are potential tivals of traditional antibodies in medicine and therapy, some challenges have to accomodated before they can be implemented clinically. </p> | <p class="intro"> Although there is no doubt that peptide aptamers are potential tivals of traditional antibodies in medicine and therapy, some challenges have to accomodated before they can be implemented clinically. </p> | ||
| − | < | + | <h3> Size of the peptide </h3> |
<p> <span class="intro"> The bigger molecule the larger risk of immunogenicity. </span> </p> | <p> <span class="intro"> The bigger molecule the larger risk of immunogenicity. </span> </p> | ||
| − | < | + | <h3> Effector mechanism </h3> |
| − | < | + | <h3> Half-life </h3> |
</html> | </html> | ||
{{:Team:SDU-Denmark/core/footer}} | {{:Team:SDU-Denmark/core/footer}} | ||
Revision as of 10:31, 12 August 2015
Medical aspects
Although there is no doubt that peptide aptamers are potential tivals of traditional antibodies in medicine and therapy, some challenges have to accomodated before they can be implemented clinically.
Size of the peptide
The bigger molecule the larger risk of immunogenicity.
Effector mechanism
Half-life